Company intelligence / Profile preview

Novatim Immune Therapeutics

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Novatim has advanced a pipeline of first-in-class and best-in-class immunotherapies targeting solid tumors and hematological malignancies. Its lead asset KY‑0301 is the world’s first nanobody-based bispecific ADC targeting c-MET and EGFR in Phase 1/2 trials in advanced solid tumors. Preclinical data show strong tumor penetration and safety. Multiple CAR-T programs are in early clinical or preclinical stages.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Antibody-drug conjugateMonoclonal antibodyNanobody therapyCAR-T cell therapyFusion protein
Industry: Biotech

Drug pipeline

9 assets

KY-0301

8 more assets in the full pipeline.

Request access →

Partnerships

SDM Bioservices—regulatory support for FDA/NMPA IND submissions for KY–0301

Beyond the preview

Go deeper on Novatim Immune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novatim Immune Therapeutics.

Explore the full profile